Diabetic nephropathy: New approaches for improving glycemic control and reducing risk

Journal of Nephrology

Volumn 26, Issue 6, 2013, Pages 975-985

  Schernthaner, Guntram ^a   Schernthaner, Gerit Holger ^b  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Diabetes; Diabetic nephropathy; Dipeptidyl peptidase 4 inhibitors; Glucagon like peptide 1 analogs; Renal safety

Indexed keywords

ALISKIREN; ALOGLIPTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; AVOSENTAN; BARDOXOLONE METHYL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; LINAGLIPTIN; LOSARTAN; PLACEBO; RENIN INHIBITOR; SAXAGLIPTIN; SITAGLIPTIN; VALSARTAN; VILDAGLIPTIN; AMIDE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ENDOTHELIN; FUMARIC ACID DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; METHYL 2-CYANO-3,12-DIOXOOLEAN-1,9-DIEN-28-OATE; OLEANOLIC ACID; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE; RENIN;

ALBUMINURIA; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GLYCEMIC CONTROL; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; TREATMENT PLANNING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COMPLICATION; COST OF ILLNESS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HYPERGLYCEMIA; METABOLISM; RISK FACTOR;

AMIDES; ANTIHYPERTENSIVE AGENTS; COST OF ILLNESS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDOTHELINS; FUMARATES; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; OLEANOLIC ACID; PURINES; QUINAZOLINES; RENIN; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 84889661242     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000281     Document Type: Review

References (84)

1. International Diabetes Federation. IDF diabetes atlas. 5th ed. Available at: http://www.idf.org/diabetesatlas/5e/the-global. Accessed May 5, 2013.
2. Steinke JM, Mauer M. International Diabetic Nephropathy Study Group. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients. Pediatr Endocrinol Rev. 2008;5(Suppl 4):958-963.
3. Bogdanović R. Diabetic nephropathy in children and adolescents. Pediatr Nephrol. 2008;23(4):507-525.
4. Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther. 2009;31(11):2608-2617.
5. Tervaert TW, Mooyaart AL, Amann K, et al. Renal Pathology Society. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21(4):556-563.
6. National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2):S12-S154.
7. Atkins RC, Zimmet P. 2010 International Society of Nephrology/International Federation of Kidney Foundations World Kidney Day Steering Committee and the International Diabetes Federation. Diabetic kidney disease: act now or pay later. Am J Med Sci. 2010; 339(2):102-104.
8. Yamagata K, Iseki K, Nitta K, et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol. 2008;12(1):1-8.
9. Centers for Disease Control and Prevention. Diabetes data and trends. Atlanta, GA: National Diabetes Surveillance System, CDC, US Department of Health and Human Services; 2010. Available at: http://www.cdc.gov/diabetes/statistics/esrd/fig7.htm. Accessed May 2, 2013.
10. Zoppini G, Targher G, Chonchol M, Perrone F, Lippi G, Muggeo M. Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2009;19(8):580-586.
11. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1): 225-232.
12. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006;55(6):1832-1839.
13. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med. 2008;25(Suppl 2):25-29.
14. Foley RN, Collins AJ. The growing economic burden of diabetic kidney disease. Curr Diab Rep. 2009;9(6):460-465.
15. Joyce AT, Iacoviello JM, Nag S, et al. End-stage renal disease-associated managed care costs among patients with and without diabetes. Diabetes Care. 2004;27(12): 2829-2835.
16. Happich M, Landgraf R, Piehlmeier W, Falkenstein P, Stamenitis S. The economic burden of nephropathy in diabetic patients in Germany in 2002. Diabetes Res Clin Pract. 2008;80(1):34-39.
17. American Diabetes Association. Standards of medical care in diabetes: 2013. Diabetes Care. 2013;36(Suppl 1):S11-S66.
18. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008; 31(1):81-86.
19. Jenssen TG, Tonstad S, Claudi T, Midthjell K, Cooper J. The gap between guidelines and practice in the treatment of type 2 diabetes: A nationwide survey in Norway. Diabetes Res Clin Pract. 2008;80(2):314-320.
20. Orozco-Beltrán D, Gil-Guillen VF, Quirce F, et al. Collaborative diabetes Study Investigators. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain. Int J Clin Pract. 2007;61(6):909-915.
21. Tiwari A. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Curr Opin Investig Drugs. 2009;10(10):1091-1104.
22. Burcelin R, Cani PD, Knauf C. Glucagon-like peptide-1 and energy homeostasis. J Nutr. 2007;137(11)(Suppl):2534S-2538S.
23. Baggio LL, Drucker D. Therapeutic applications of DPPIV inhibitors: incretin actions and blood glucose regulation. Medscape Education. 2010. http://www.medscape.org/viewarticle/530215_2. Accessed May 13, 2013.
24. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-Amino-piperidin-1-yl)-7-but-2ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008;325(1):175-182.
25. Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens. 2003;21(6):1125-1135.
26. Carraro-Lacroix LR, Malnic G, Girardi AC. Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol. 2009;297(6):F1647-F1655.
27. Park CW, Kim HW, Ko SH, et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/ db mice. J Am Soc Nephrol. 2007;18(4):1227-1238.
28. Barnett AH. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy. Adv Ther. 2011;28(6): 447-459.
29. Forst T, Pfützner A. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. Expert Opin Pharmacother. 2012;13(1):101-110.
30. Subbarayan S, Kipnes M. Sitagliptin: a review. Expert Opin Pharmacother. 2011;12(10):1613-1622.
31. Yang LP. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. Drugs. 2012;72(2):229-248.
32. Kalra S. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes. J Assoc Physicians India. 2011;59:237-245.
33. Ghatak SB, Patel DS, Shanker N, Srivstava A, Deshpande SS, Panchal SJ. Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus. Curr Diabetes Rev. 2010;6(6):410-421.
34. Gerich J. DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract. 2010;90(2):131-140.
35. Gooben K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2012. [Epub ahead of print].
36. Hüttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol. 2008;48(10):1171-1178.
37. Bristol Myers Squibb/AstraZeneca EEIG. Summary of product characteristics: Onglyza 5 mg film-coated tablets. Available at: http://www.medicines.org.uk/EMC/medicine/22315/SPC/Onglyza+5mg+film-coated+tablets. Accessed May 5, 2013.
38. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes Obes Metab. 2011; 13(10):939-946.
39. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010;12(8):648-658.
40. Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010;38(4):667-678.
41. Novartis Pharmaceuticals. NPU. Summary of product characteristics: Galvus 50 mg film-coated tablets. Available at: http://www.medicines.org.uk/EMC/medicine/20734/SPC/Galvus+50+mg+Tablets/. Accessed May 2, 2013.
42. Merck Sharpe & Dohme. Summary of product characteristics: Januvia 25mg, 50mg, 100mg film-coated tablets. Available at: http://www.medicines.org.uk/EMC/medicine/19609/SPC/JANUVIA+100mg+film-coated+tablets. Accessed May 2, 2013.
43. Retlich S, Withopf B, Greischel A, Staab A, Jaehde U, Fuchs H. Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356): investigations in DPP-4 deficient and wildtype rats. Biopharm Drug Dispos. 2009;30 (8):422-436.
44. Fuchs H, Tillement JP, Urien S, Greischel A, Roth W. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol. 2009;61(1):55-62.
45. Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009;11(8):786-794.
46. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996;137(7):2968-2978.
47. Wei Y, Mojsov S. Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol Scand. 1996;157(3): 355-357.
48. Chaykovska L, von Websky K, Rahnenführer J, et al. Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS ONE. 2011;6(11):e27861.
49. Mega C, de Lemos ET, Vala H, et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res. 2011;2011:162092.
50. Tofovic DS, Bilan VP, Jackson EK. Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome. Clin Exp Pharmacol Physiol. 2010;37(7):689-691.
51. Liu WJ, Xie SH, Liu YN, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther. 2012;340(2):248-255.
52. Alter ML, Ott IM, von Websky K, et al. DPP-4 Inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res. 2012;36(1):119-130.
53. Groop PH, Cooper M, Perkovic V, Emser A, Von Eynatten M, Woerle HJ. Linagliptin lowers albuminuria on top of recommended standard treatment for diabetic nephropathy [abstract]. Diabetes. 2012;61:A243.
54. Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactivehemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension. 2010;56(4):728-733.
55. Levey AS, Coresh J, Balk E, et al. National Kidney Foun-dation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137-147.
56. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-1305.
57. Wu AY, Kong NC, de Leon FA, et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia. 2005;48(1):17-26.
58. Shlipak MG, Smith GL, Rathore SS, Massie BM, Krumholz HM. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. J Am Soc Nephrol. 2004;15(8):2195-2203.
59. Groop PH, Thomas MC, Moran JL, et al. FinnDiane Study Group. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009; 58(7):1651-1658.
60. Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol. 2008;19(1):182-187.
61. Lou Arnal LM, Campos Gutiérrez B, Cuberes Izquierdo M, et al. Grupo de Investigación ERC Aragón. [Prevalence of chronic kidney disease in patients with type 2 diabetes mellitus treated in primary care] [article in Spanish]. Nefrologia. 2010;30(5):552-556.
62. Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab. 2011;12(1):57-69.
63. Schernthaner G, Ritz E, Schernthaner GH. Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly? Nephrol Dial Transplant. 2010;25(7):2044-2047.
64. Haneda M, Morikawa A. Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how? Nephrol Dial Transplant. 2009;24(2):338-341.
65. Holstein A, Plaschke A, Hammer C, Egberts EH. Characteristics and time course of severe glimepirideversus glibenclamide-induced hypoglycaemia. Eur J Clin Pharmacol. 2003;59(2):91-97.
66. Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care. 2011;34(Suppl 2): S132-S137.
67. Zoungas S, Patel A, Chalmers J, et al. ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410-1418.
68. Rocha A, Almeida M, Santos J, Carvalho A. Metformin in patients with chronic kidney disease: strengths and weaknesses. J Nephrol. 2013;26(1):55-60.
69. Brunelli SM, Thadhani R, Ikizler TA, Feldman HI. Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes. Kidney Int. 2009;75(9):961-968.
70. Turgut F, Bolton WK. Potential new therapeutic agents for diabetic kidney disease. Am J Kidney Dis. 2010;55(5):928-940.
71. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434-444.
72. Cushman WC, Evans GW, Byington RP, et al. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575-1585.
73. Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol. 2005;16(10):3027-3037.
74. Gupta A, Gupta P, Biyani M. Targeted therapies in diabetic nephropathy: an update. J Nephrol. 2011;24(6):686-695.
75. Pinto R, Gradman AH. Direct renin inhibition: an update. Curr Hypertens Rep. 2009;11(6):456-462.
76. Dong YF, Liu L, Lai ZF, et al. Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. J Hypertens. 2010;28(7):1554-1565.
77. Parving HH, Brenner BM, McMurray JJ, et al. ALTITUDE Investigators. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst. 2012;13(3): 387-393.
78. McMurray JJ, Abraham WT, Dickstein K, Køber L, Massie BM, Krum H. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail. 2012;14(4):341-343.
79. Liby K, Hock T, Yore MM, et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res. 2005; 65(11):4789-4798.
80. Pergola PE, Raskin P, Toto RD, et al. BEAM Study Investigators. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011;365(4):327-336.
81. Pergola PE, Krauth M, Huff JW, et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol. 2011;33(5):469-476.
82. RamachandraRao SP, Zhu Y, Ravasi T, et al. Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol. 2009;20(8):1765-1775.
83. Wenzel RR, Littke T, Kuranoff S, et al. SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study Investigators. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol. 2009;20(3):655-664.
84. Radbill B, Murphy B, LeRoith D. Rationale and strategies for early detection and management of diabetic kidney disease. Mayo Clin Proc. 2008;83(12):1373-1381.